Noile-Immune Biotech Inc.
Notice on Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Clause
Monthly disclosure of the exercise status of stock acquisition rights. The target month is October 2026, with 1,410,000 shares exercised, 14,100 stock acquisition rights exercised, more than 50,000 shares remaining unexercised, and total outstanding shares of 43,399,118 shares. The exercise restriction ratio is 3.25%.
Key Figures
- Number of shares delivered in the target month: 1,410,000 shares
- Number of unexercised stock acquisition rights: 85,900 rights
- Outstanding shares (as of target month): 43,399,118 shares
AI要約
IR Highlights
Noile-Immune Biotech Inc. announced the monthly exercise status for stock acquisition rights with an exercise price adjustment clause issued in October 2026. During the period, the number of shares actually exercised was 1,410,000 shares, the total number of stock acquisition rights exercised was 14,100 rights, and the average exercise price of the exercised shares was not disclosed. Unexercised stock acquisition rights total 85,900 rights, and the exercise restriction ratio at the end of the previous month was 3.25%.
Impact on Shareholders and Outlook
This disclosure is a routine follow-up on the exercise status of stock acquisition rights and is viewed as having a limited immediate direct impact on capital structure or dilution. Compliance with exercise restrictions is being managed appropriately, and depending on future exercise activity there is potential to affect the number of outstanding shares.
Noile-Immune Biotech Inc.
Company overview · Stock price · Financial data · All IR
